- Home
- VTAK vs QLGN Comparison
VTAK vs QLGN Comparison
Compare VTAK & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTAK
- QLGN
- Stock Information
- Founded
- VTAK 2002
- QLGN 1996
- Country
- VTAK United States
- QLGN United States
- Employees
- VTAK N/A
- QLGN N/A
- Industry
- VTAK Medical/Dental Instruments
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- VTAK Health Care
- QLGN Health Care
- Exchange
- VTAK Nasdaq
- QLGN Nasdaq
- Market Cap
- VTAK 3.1M
- QLGN 3.1M
- IPO Year
- VTAK 2018
- QLGN N/A
- Fundamental
- Price
- VTAK $2.45
- QLGN $2.10
- Analyst Decision
- VTAK
- QLGN
- Analyst Count
- VTAK 0
- QLGN 0
- Target Price
- VTAK N/A
- QLGN N/A
- AVG Volume (30 Days)
- VTAK 3.1M
- QLGN 42.8K
- Earning Date
- VTAK 08-11-2025
- QLGN 08-14-2025
- Dividend Yield
- VTAK N/A
- QLGN N/A
- EPS Growth
- VTAK N/A
- QLGN N/A
- EPS
- VTAK N/A
- QLGN N/A
- Revenue
- VTAK $600,000.00
- QLGN N/A
- Revenue This Year
- VTAK $822.86
- QLGN N/A
- Revenue Next Year
- VTAK $168.42
- QLGN N/A
- P/E Ratio
- VTAK N/A
- QLGN N/A
- Revenue Growth
- VTAK 37.62
- QLGN N/A
- 52 Week Low
- VTAK $2.36
- QLGN $1.61
- 52 Week High
- VTAK $33.06
- QLGN $10.45
- Technical
- Relative Strength Index (RSI)
- VTAK 39.41
- QLGN 56.76
- Support Level
- VTAK $2.36
- QLGN $1.66
- Resistance Level
- VTAK $2.55
- QLGN $2.16
- Average True Range (ATR)
- VTAK 0.14
- QLGN 0.11
- MACD
- VTAK 0.03
- QLGN 0.08
- Stochastic Oscillator
- VTAK 14.25
- QLGN 87.17
About VTAK Catheter Precision Inc.
Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.